Biosergen AB (publ) (STO:BIOSGN)
Sweden
· Delayed Price · Currency is SEK 37.00
-1.00 (-2.63%)
Mar 9, 2026, 2:38 PM CET
Biosergen AB Company Description
Biosergen AB (publ), a biotech company, develops antifungal products.
Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients.
The company was founded in 2004 and is based in Solna, Sweden.
Biosergen AB (publ)
| Country | Sweden |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Tine Olesen |
Contact Details
Address: Fogdevreten 2 Solna, 171 65 Sweden | |
| Phone | 45 3 13 55 707 |
| Website | biosergen.net |
Stock Details
| Ticker Symbol | BIOSGN |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0016013460 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tine Kold Olesen Ph.D. | Chief Executive Officer and Member of Executive Board |
| Mark Beveridge | Chief Financial Officer |
| Sergey B. Zotchev Ph.D. | Chief Scientific Officer and Member of Scientific Advisory Panel |